| 1 | Affinity maturation of antibody responses is mediated by differential plasma cell proliferation | 38.2 | 0 | Citations (PDF) |
| 2 | Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern | 13.1 | 0 | Citations (PDF) |
| 3 | Role of affinity in plasma cell development in the germinal center light zone | 8.1 | 3 | Citations (PDF) |
| 4 | SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity | 4.5 | 5 | Citations (PDF) |
| 5 | Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques | 38.2 | 5 | Citations (PDF) |
| 6 | Transcription of HIV-1 at sites of intact latent provirus integration | 8.1 | 1 | Citations (PDF) |
| 7 | Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape | 14.1 | 25 | Citations (PDF) |
| 8 | CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals | 14.0 | 4 | Citations (PDF) |
| 9 | Memory B cell development elicited by mRNA booster vaccinations in the elderly | 8.1 | 5 | Citations (PDF) |
| 10 | Impact of misclassified defective proviruses on HIV reservoir measurements | 14.1 | 10 | Citations (PDF) |
| 11 | Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial | 25.6 | 23 | Citations (PDF) |
| 12 | Continually recruited naïve T cells contribute to the follicular helper and regulatory T cell pools in germinal centers | 14.1 | 8 | Citations (PDF) |
| 13 | Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing | 7.7 | 51 | Citations (PDF) |
| 14 | Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial | 12.5 | 44 | Citations (PDF) |
| 15 | Germinal Centers | 30.9 | 350 | Citations (PDF) |
| 16 | Plasma Neutralization of the SARS-CoV-2 Omicron Variant | 25.5 | 322 | Citations (PDF) |
| 17 | Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer | 14.1 | 15 | Citations (PDF) |
| 18 | Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins | 22.7 | 81 | Citations (PDF) |
| 19 | Prolonged viral suppression with anti-HIV-1 antibody therapy | 40.1 | 101 | Citations (PDF) |
| 20 | Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost | 40.1 | 185 | Citations (PDF) |
| 21 | Inflammasome activation in infected macrophages drives COVID-19 pathology | 40.1 | 315 | Citations (PDF) |
| 22 | Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection | 0.8 | 5 | Citations (PDF) |
| 23 | The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies | 7.7 | 132 | Citations (PDF) |
| 24 | Combination anti-HIV antibodies provide sustained virological suppression | 40.1 | 93 | Citations (PDF) |
| 25 | CRISPR comes a-knock-in to reprogram antibodies in vivo | 18.1 | 1 | Citations (PDF) |
| 26 | Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans | 8.1 | 12 | Citations (PDF) |
| 27 | Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants | 8.1 | 4 | Citations (PDF) |
| 28 | Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens | 8.1 | 11 | Citations (PDF) |
| 29 | A naturally arising broad and potent CD4-binding site antibody with low somatic mutation | 11.3 | 10 | Citations (PDF) |
| 30 | Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans | 8.1 | 35 | Citations (PDF) |
| 31 | Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial | 25.6 | 55 | Citations (PDF) |
| 32 | HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design | 14.1 | 7 | Citations (PDF) |
| 33 | Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity | 14.1 | 35 | Citations (PDF) |
| 34 | Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination | 40.1 | 68 | Citations (PDF) |
| 35 | Enhanced SARS-CoV-2 neutralization by dimeric IgA | 13.1 | 342 | Citations (PDF) |
| 36 | Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates | 3.6 | 18 | Citations (PDF) |
| 37 | Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia | 8.1 | 37 | Citations (PDF) |
| 38 | Evolution of antibody immunity to SARS-CoV-2 | 40.1 | 1,210 | Citations (PDF) |
| 39 | Persistent cellular immunity to SARS-CoV-2 infection | 8.1 | 93 | Citations (PDF) |
| 40 | Dynamic regulation of TFH selection during the germinal centre reaction | 40.1 | 65 | Citations (PDF) |
| 41 | mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants | 40.1 | 996 | Citations (PDF) |
| 42 | Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA | 3.6 | 46 | Citations (PDF) |
| 43 | A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls | 10.0 | 14 | Citations (PDF) |
| 44 | Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice | 40.1 | 98 | Citations (PDF) |
| 45 | Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease | 8.1 | 34 | Citations (PDF) |
| 46 | TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability | 1.1 | 11 | Citations (PDF) |
| 47 | Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virusAids, 2021, 35, 1567-1574 | 2.6 | 5 | Citations (PDF) |
| 48 | Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | 40.1 | 521 | Citations (PDF) |
| 49 | Germinal center–dependent and –independent memory B cells produced throughout the immune response | 8.1 | 64 | Citations (PDF) |
| 50 | Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants | 40.1 | 160 | Citations (PDF) |
| 51 | Vaccine Breakthrough Infections with SARS-CoV-2 Variants | 25.5 | 543 | Citations (PDF) |
| 52 | Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques | 4.5 | 13 | Citations (PDF) |
| 53 | Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies | 14.1 | 255 | Citations (PDF) |
| 54 | Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice | 6.4 | 38 | Citations (PDF) |
| 55 | Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York | 14.1 | 71 | Citations (PDF) |
| 56 | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations | 22.7 | 202 | Citations (PDF) |
| 57 | Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths | 14.0 | 407 | Citations (PDF) |
| 58 | Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies | 6.4 | 62 | Citations (PDF) |
| 59 | High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape | 40.1 | 139 | Citations (PDF) |
| 60 | Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption | 13.1 | 53 | Citations (PDF) |
| 61 | Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo | 8.1 | 220 | Citations (PDF) |
| 62 | Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination | 40.1 | 204 | Citations (PDF) |
| 63 | Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope | 5.8 | 2 | Citations (PDF) |
| 64 | Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence | 8.1 | 36 | Citations (PDF) |
| 65 | Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env | 13.1 | 31 | Citations (PDF) |
| 66 | A humanized mouse model of chronic COVID-19 | 18.1 | 73 | Citations (PDF) |
| 67 | Isolation of single HIV-1 Envelope specific B cells and antibody cloning from immunized rhesus macaques | 1.5 | 11 | Citations (PDF) |
| 68 | ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens | 7.3 | 56 | Citations (PDF) |
| 69 | Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells | 7.7 | 16 | Citations (PDF) |
| 70 | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies | 40.1 | 1,059 | Citations (PDF) |
| 71 | Convergent antibody responses to SARS-CoV-2 in convalescent individuals | 40.1 | 1,358 | Citations (PDF) |
| 72 | Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration | 2.6 | 12 | Citations (PDF) |
| 73 | We are here for you and ready to hear from you | 8.1 | 0 | Citations (PDF) |
| 74 | Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses | 8.1 | 409 | Citations (PDF) |
| 75 | Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir | 8.1 | 74 | Citations (PDF) |
| 76 | Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell FatesCell, 2020, 183, 1298-1311.e11 | 35.1 | 141 | Citations (PDF) |
| 77 | JEM goes viral | 8.1 | 0 | Citations (PDF) |
| 78 | An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells | 7.7 | 16 | Citations (PDF) |
| 79 | Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 | 38.2 | 1,612 | Citations (PDF) |
| 80 | Autoantibodies against type I IFNs in patients with life-threatening COVID-19 | 38.2 | 1,884 | Citations (PDF) |
| 81 | Recommendations for measuring HIV reservoir size in cure-directed clinical trials | 25.6 | 91 | Citations (PDF) |
| 82 | Single-Cell Sorting of HBsAg-Binding Memory B Cells from Human Peripheral Blood Mononuclear Cells and Antibody Cloning | 1.1 | 7 | Citations (PDF) |
| 83 | Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesCell, 2020, 182, 828-842.e16 | 35.1 | 542 | Citations (PDF) |
| 84 | A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations | 15.2 | 51 | Citations (PDF) |
| 85 | Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies | 14.1 | 13 | Citations (PDF) |
| 86 | A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques | 7.7 | 22 | Citations (PDF) |
| 87 | Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin | 3.6 | 24 | Citations (PDF) |
| 88 | Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody | 7.7 | 8 | Citations (PDF) |
| 89 | All eyes on a hurdle race for a SARS-CoV-2 vaccine | 40.1 | 19 | Citations (PDF) |
| 90 | Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity | 25.6 | 111 | Citations (PDF) |
| 91 | Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 2020, , | | 28 | Citations (PDF) |
| 92 | Risk of Zika microcephaly correlates with features of maternal antibodies | 8.1 | 40 | Citations (PDF) |
| 93 | Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study | 2.5 | 61 | Citations (PDF) |
| 94 | Protein Amounts of the MYC Transcription Factor Determine Germinal Center B Cell Division Capacity | 22.7 | 111 | Citations (PDF) |
| 95 | Anti-idiotypic antibodies elicit anti-HIV-1–specific B cell responses | 8.1 | 22 | Citations (PDF) |
| 96 | Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir | 8.1 | 81 | Citations (PDF) |
| 97 | JEM Editorial Board: Expanding on the basis of cancer | 8.1 | 0 | Citations (PDF) |
| 98 | Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption | 3.6 | 54 | Citations (PDF) |
| 99 | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope | 22.7 | 66 | Citations (PDF) |
| 100 | Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques | 40.1 | 122 | Citations (PDF) |
| 101 | HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells | 8.1 | 72 | Citations (PDF) |
| 102 | Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic | 25.6 | 178 | Citations (PDF) |
| 103 | Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation | 25.6 | 103 | Citations (PDF) |
| 104 | A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection | 25.6 | 87 | Citations (PDF) |
| 105 | Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity | 7.7 | 73 | Citations (PDF) |
| 106 | Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope | 14.1 | 72 | Citations (PDF) |
| 107 | Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells | 3.6 | 34 | Citations (PDF) |
| 108 | Relationship between intact HIV-1 proviruses in circulating CD4
<sup>+</sup>
T cells and rebound viruses emerging during treatment interruption | 7.7 | 58 | Citations (PDF) |
| 109 | The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination | 14.2 | 31 | Citations (PDF) |
| 110 | Combination therapy with anti-HIV-1 antibodies maintains viral suppression | 40.1 | 372 | Citations (PDF) |
| 111 | Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals | 25.6 | 188 | Citations (PDF) |
| 112 | Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion | 15.2 | 74 | Citations (PDF) |
| 113 | Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117 | 8.1 | 87 | Citations (PDF) |
| 114 | Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency | 13.1 | 94 | Citations (PDF) |
| 115 | Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections | 4.5 | 65 | Citations (PDF) |
| 116 | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller | 13.1 | 120 | Citations (PDF) |
| 117 | A time of change | 8.1 | 2 | Citations (PDF) |
| 118 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals | 25.6 | 374 | Citations (PDF) |
| 119 | RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks | 8.1 | 17 | Citations (PDF) |
| 120 | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and MexicoCell, 2017, 169, 597-609.e11 | 35.1 | 247 | Citations (PDF) |
| 121 | HIV: Persistence through division | 8.1 | 1 | Citations (PDF) |
| 122 | Early antibody therapy can induce long-lasting immunity to SHIV | 40.1 | 245 | Citations (PDF) |
| 123 | Progress toward active or passive HIV-1 vaccination | 8.1 | 104 | Citations (PDF) |
| 124 | The cell cycle restricts activation-induced cytidine deaminase activity to early G1 | 8.1 | 54 | Citations (PDF) |
| 125 | Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo | 8.1 | 128 | Citations (PDF) |
| 126 | The microanatomic segregation of selection by apoptosis in the germinal center | 38.2 | 193 | Citations (PDF) |
| 127 | Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In VivoCell, 2017, 170, 637-648.e10 | 35.1 | 111 | Citations (PDF) |
| 128 | JEM Advisory Editorial Board: Increasing diversity | 8.1 | 1 | Citations (PDF) |
| 129 | The new face of JEM | 8.1 | 0 | Citations (PDF) |
| 130 | Author response: Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies 2017, , | | 0 | Citations (PDF) |
| 131 | Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection | 4.5 | 152 | Citations (PDF) |
| 132 | Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice | 14.1 | 135 | Citations (PDF) |
| 133 | Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory | 22.7 | 107 | Citations (PDF) |
| 134 | Inducible targeting of cDCs and their subsets in vivo | 1.5 | 57 | Citations (PDF) |
| 135 | A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges | 40.1 | 263 | Citations (PDF) |
| 136 | Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin MiceCell, 2016, 166, 1445-1458.e12 | 35.1 | 235 | Citations (PDF) |
| 137 | HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies | 22.7 | 293 | Citations (PDF) |
| 138 | Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA | 7.7 | 143 | Citations (PDF) |
| 139 | Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site | 6.4 | 153 | Citations (PDF) |
| 140 | Human studies at JEM: Immunology and beyond | 8.1 | 3 | Citations (PDF) |
| 141 | Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs | 8.1 | 113 | Citations (PDF) |
| 142 | Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy | 25.5 | 62 | Citations (PDF) |
| 143 | Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and PotencyCell, 2016, 165, 1609-1620 | 35.1 | 119 | Citations (PDF) |
| 144 | HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption | 40.1 | 381 | Citations (PDF) |
| 145 | Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation | 8.1 | 98 | Citations (PDF) |
| 146 | Towards HIV-1 remission: potential roles for broadly neutralizing antibodies | 9.1 | 59 | Citations (PDF) |
| 147 | Author response: Structural basis for germline antibody recognition of HIV-1 immunogens 2016, , | | 0 | Citations (PDF) |
| 148 | A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo | 4.5 | 44 | Citations (PDF) |
| 149 | Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsCell, 2015, 161, 1280-1292 | 35.1 | 257 | Citations (PDF) |
| 150 | Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow | 8.1 | 208 | Citations (PDF) |
| 151 | Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient | 1.5 | 8 | Citations (PDF) |
| 152 | AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges | 40.1 | 249 | Citations (PDF) |
| 153 | Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1 | 35.1 | 99 | Citations (PDF) |
| 154 | HIV-1 Integration Landscape during Latent and Active Infection | 35.1 | 348 | Citations (PDF) |
| 155 | Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes | 3.6 | 116 | Citations (PDF) |
| 156 | Circulating precursors of human CD1c+ and CD141+ dendritic cells | 8.1 | 171 | Citations (PDF) |
| 157 | Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin MiceCell, 2015, 161, 1505-1515 | 35.1 | 210 | Citations (PDF) |
| 158 | Collecting Lymphatic Vessel Permeability Facilitates Adipose Tissue Inflammation and Distribution of Antigen to Lymph Node–Homing Adipose Tissue Dendritic Cells | 0.6 | 99 | Citations (PDF) |
| 159 | Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 | 40.1 | 621 | Citations (PDF) |
| 160 | Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike | 14.1 | 76 | Citations (PDF) |
| 161 | Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma | 35.1 | 130 | Citations (PDF) |
| 162 | Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching | 40.1 | 87 | Citations (PDF) |
| 163 | Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas | 4.5 | 20 | Citations (PDF) |
| 164 | Clonal analysis of human dendritic cell progenitor using a stromal cell culture | 1.5 | 32 | Citations (PDF) |
| 165 | An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex | 2.8 | 38 | Citations (PDF) |
| 166 | Epigenetic targeting of activation-induced cytidine deaminase | 7.7 | 46 | Citations (PDF) |
| 167 | Convergent Transcription at Intragenic Super-Enhancers Targets AID-Initiated Genomic InstabilityCell, 2014, 159, 1538-1548 | 35.1 | 205 | Citations (PDF) |
| 168 | B Cell Super-Enhancers and Regulatory Clusters Recruit AID Tumorigenic ActivityCell, 2014, 159, 1524-1537 | 35.1 | 217 | Citations (PDF) |
| 169 | Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants | 8.1 | 71 | Citations (PDF) |
| 170 | L-Myc expression by dendritic cells is required for optimal T-cell priming | 40.1 | 64 | Citations (PDF) |
| 171 | Clonal selection in the germinal centre by regulated proliferation and hypermutation | 40.1 | 443 | Citations (PDF) |
| 172 | A robust pipeline for rapid production of versatile nanobody repertoires | 14.5 | 338 | Citations (PDF) |
| 173 | Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques | 8.1 | 268 | Citations (PDF) |
| 174 | Identification of chromosomal translocation hotspots via scan statistics | 5.0 | 23 | Citations (PDF) |
| 175 | Classical Flt3L-dependent dendritic cells control immunity to protein vaccine | 8.1 | 87 | Citations (PDF) |
| 176 | Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice | 35.1 | 317 | Citations (PDF) |
| 177 | Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo ActivityCell, 2014, 158, 1243-1253 | 35.1 | 392 | Citations (PDF) |
| 178 | Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy | 35.1 | 282 | Citations (PDF) |
| 179 | Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike | 6.4 | 182 | Citations (PDF) |
| 180 | Antigen Delivery to CD11c+CD8− Dendritic Cells Induces Protective Immune Responses against Experimental Melanoma in Mice In Vivo | 0.6 | 59 | Citations (PDF) |
| 181 | Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | 22.7 | 291 | Citations (PDF) |
| 182 | Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160ΔcBaL | 1.5 | 8 | Citations (PDF) |
| 183 | HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice | 7.7 | 228 | Citations (PDF) |
| 184 | Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys | 40.1 | 546 | Citations (PDF) |
| 185 | Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia | 40.1 | 396 | Citations (PDF) |
| 186 | Antibodies in HIV-1 Vaccine Development and Therapy | 38.2 | 393 | Citations (PDF) |
| 187 | Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody | 7.7 | 55 | Citations (PDF) |
| 188 | Chromosome Translocation, B Cell Lymphoma, and Activation-Induced Cytidine Deaminase | 31.8 | 146 | Citations (PDF) |
| 189 | Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization | 35.1 | 427 | Citations (PDF) |
| 190 | Roadmaps to a vaccine | 40.1 | 26 | Citations (PDF) |
| 191 | Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model | 3.6 | 21 | Citations (PDF) |
| 192 | Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission | 8.1 | 137 | Citations (PDF) |
| 193 | Computational analysis of anti–HIV-1 antibody neutralization panel data to identify potential functional epitope residues | 7.7 | 91 | Citations (PDF) |
| 194 | Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains | 3.6 | 62 | Citations (PDF) |
| 195 | Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies | 8.1 | 83 | Citations (PDF) |
| 196 | Enhanced HIV-1 neutralization by antibody heteroligation | 7.7 | 46 | Citations (PDF) |
| 197 | Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 | 7.7 | 193 | Citations (PDF) |
| 198 | A mouse model for HIV-1 entry | 7.7 | 68 | Citations (PDF) |
| 199 | Complex-type
<i>N</i>
-glycan recognition by potent broadly neutralizing HIV antibodies | 7.7 | 460 | Citations (PDF) |
| 200 | Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomasBlood, 2012, 120, 2240-2248 | 1.0 | 302 | Citations (PDF) |
| 201 | HIV therapy by a combination of broadly neutralizing antibodies in humanized mice | 40.1 | 426 | Citations (PDF) |
| 202 | A Blueprint for HIV Vaccine Discovery | 15.2 | 327 | Citations (PDF) |
| 203 | The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry | 13.1 | 370 | Citations (PDF) |
| 204 | Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein | 8.1 | 135 | Citations (PDF) |
| 205 | Germinal Centers | 30.9 | 1,553 | Citations (PDF) |
| 206 | Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage | 8.1 | 412 | Citations (PDF) |
| 207 | Translocation capture sequencing: A method for high throughput mapping of chromosomal rearrangements | 1.5 | 21 | Citations (PDF) |
| 208 | Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses | 2.5 | 94 | Citations (PDF) |
| 209 | Translocation-Capture Sequencing Reveals the Extent and Nature of Chromosomal Rearrangements in B Lymphocytes | 35.1 | 302 | Citations (PDF) |
| 210 | Differential regulation of self-reactivity discriminates between IgG<sup>+</sup>human circulating memory B cells and bone marrow plasma cells | 7.7 | 74 | Citations (PDF) |
| 211 | A dynamic T cell–limited checkpoint regulates affinity-dependent B cell entry into the germinal center | 8.1 | 325 | Citations (PDF) |
| 212 | Ralph Steinman (1943–2011) | 40.1 | 6 | Citations (PDF) |
| 213 | Polyreactive antibodies in adaptive immune responses to viruses | 5.6 | 100 | Citations (PDF) |
| 214 | Development and Migration of Plasma Cells in the Mouse Lymph Node | 22.7 | 113 | Citations (PDF) |
| 215 | Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | 40.1 | 361 | Citations (PDF) |
| 216 | Anti-gp41 Antibodies Cloned from HIV-Infected Patients with Broadly Neutralizing Serologic Activity | 3.6 | 47 | Citations (PDF) |
| 217 | Human anti–HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness | 8.1 | 56 | Citations (PDF) |
| 218 | Origin of Chromosomal Translocations in Lymphoid Cancer | 35.1 | 252 | Citations (PDF) |
| 219 | Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter | 35.1 | 926 | Citations (PDF) |
| 220 | Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | 38.2 | 961 | Citations (PDF) |
| 221 | Germinal center reutilization by newly activated B cells | 8.1 | 88 | Citations (PDF) |
| 222 | A method for identification of HIV gp140 binding memory B cells in human blood | 1.5 | 175 | Citations (PDF) |
| 223 | Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | 40.1 | 741 | Citations (PDF) |
| 224 | AID Produces DNA Double-Strand Breaks in Non-Ig Genes and Mature B Cell Lymphomas with Reciprocal Chromosome Translocations | 14.2 | 205 | Citations (PDF) |
| 225 | Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning | 1.5 | 820 | Citations (PDF) |
| 226 | AID Is Required for the Chromosomal Breaks in c-myc that Lead to c-myc/IgH TranslocationsCell, 2008, 135, 1028-1038 | 35.1 | 372 | Citations (PDF) |
| 227 | Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors | 7.7 | 197 | Citations (PDF) |
| 228 | Autoreactivity in Human IgG+ Memory B Cells | 22.7 | 411 | Citations (PDF) |
| 229 | T-independent type II immune responses generate memory B cells | 8.1 | 230 | Citations (PDF) |
| 230 | Somatic Hypermutation Is Limited by CRM1-dependent Nuclear Export of Activation-induced Deaminase | 8.1 | 195 | Citations (PDF) |
| 231 | Predominant Autoantibody Production by Early Human B Cell Precursors | 38.2 | 1,654 | Citations (PDF) |
| 232 | OcaB regulates transitional B cell selection | 3.4 | 20 | Citations (PDF) |
| 233 | Role of antigen receptor affinity in T cell–independent antibody responses in vivo | 13.1 | 221 | Citations (PDF) |
| 234 | Role of BCR affinity in T cell–dependent antibody responses in vivo | 13.1 | 253 | Citations (PDF) |
| 235 | AID is required to initiate Nbs1/γ-H2AX focus formation and mutations at sites of class switching | 40.1 | 433 | Citations (PDF) |
| 236 | Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo | 8.1 | 1,536 | Citations (PDF) |
| 237 | Circulating human B cells that express surrogate light chains and edited receptors | 13.1 | 105 | Citations (PDF) |
| 238 | Antibody regulation of B cell development | 13.1 | 209 | Citations (PDF) |
| 239 | DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation | 40.1 | 468 | Citations (PDF) |
| 240 | A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells | 1.0 | 108 | Citations (PDF) |
| 241 | Secondary V(D)J recombination in B-1 cells | 40.1 | 61 | Citations (PDF) |
| 242 | V(D)J Recombination: Modulation of RAG1 and RAG2 Cleavage Activity on 12/23 Substrates by Whole Cell Extract and DNA-bending Proteins | 8.1 | 122 | Citations (PDF) |
| 243 | Requirement for Ku80 in growth and immunoglobulin V(D)J recombination | 40.1 | 574 | Citations (PDF) |
| 244 | The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes | 40.1 | 226 | Citations (PDF) |
| 245 | The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing | 40.1 | 801 | Citations (PDF) |
| 246 | Structural basis for germline antibody recognition of HIV-1 immunogens | 1.6 | 61 | Citations (PDF) |
| 247 | Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies | 1.6 | 39 | Citations (PDF) |
| 248 | Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants | 1.6 | 961 | Citations (PDF) |
| 249 | A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch | 1.6 | 10 | Citations (PDF) |
